Skip to content

Detecting Traumatic Intracranial Hemorrhage With Microwaves and Biomarkers

Detecting Traumatic Intracranial Hemorrhage With Microwaves and Biomarkers: A Prospective Study Evaluating Ability of Microwave Scanning in Conjunction With Biomarkers to Diagnose Traumatic Intracranial Hemorrhage

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04666766
Acronym
MBI01
Enrollment
450
Registered
2020-12-14
Start date
2021-09-01
Completion date
2026-01-12
Last updated
2023-01-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Biomarkers, Brain Injuries, Traumatic, Microwave Imaging

Keywords

Microwave Imaging

Brief summary

This study will evaluate if traumatic intracranial hemorrhage can be safely ruled out by using a microwave scanner (MD100) in conjunction with a combination of different brain biomarkers analyzed in serum.

Detailed description

This is a prospective, open, multicentre trial that will enrol patients presenting to the Emergency Department (ED) because of isolated head trauma or head trauma as part of a multi trauma. Microwave scanning characteristics and biomarkers in patients with traumatic intracranial haemorrhage (TICH) (Group A) will be compared to patients with head trauma that do not have TICH (Group B). All adult patients with trauma to the head will be eligible for inclusion if a medical professional has evaluated the risk of spine injury. After additional physical examination, control of inclusion- and exclusion criteria and after informed consent has been acquired, the microwave measurement and blood sampling will be performed. Before enrolment in the study, and in the acute phase, one of the investigators or a member of the investigator staff must explain verbally the implications of study participation to the patient, and the patient is asked to give a verbal consent. As soon as is practically possible after the acute phase of the disease, the patient will sign and personally date the informed consent form. In cases where the patient is not capable to read and/or sign the informed consent, due to disability, an independent witness shall be present throughout the process of reading the written informed consent and any other information aloud and explained to the prospective patient. As an independent witness, healthcare professionals who are not responsible or in any way involved in the patient's care or treatment are accepted. The independent witness can sign on the behalf of the patient in the presence of the patient and the Investigator. More details of the informed consent procedure are described in this Clinical Investigation Plan, section 6.3. The microwave measurement will take less than five minutes (the duration of the actual measurement is about 1,5 min and will not interfere with the patient's standard of care). The Research Nurse or the Investigator documents all patient clinical trial information in the eCRF. Safety and usability will be evaluated throughout the trial, and a safety follow-up will be performed by the Research Nurse or Investigator approximately 24 hours after the measurement procedure. During the data processing phase of study, the result of the microwave measurement will be compared to the result of the biomarkers, CT examination and the patient's final diagnosis. As a control group, approximately 50 demographically matched healthy volunteers (Group C) will be asked to participate in the trial. The trial will provide knowledge of the predictive value of microwave measurement and biomarkers for the diagnosis of intracranial haemorrhages in the acute TBI phase.

Interventions

DEVICEMicrowave scanning of the head

A scan of the head will be performed with a microwave device to ascertain the likelihood of intracranial hemorrhage.

Sponsors

Medfield Diagnostics
CollaboratorINDUSTRY
Region Skane
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
DOUBLE (Subject, Caregiver)

Masking description

No results of the biomarker assays or microwave scans will be visible to the care givers or the participants.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

(groups A and B): * Verbal Informed Consent in the acute phase. * Signed Informed Consent Form after the acute phase. On behalf of the patient, independent witness signed informed consent (in cases where the patient is unable to sign). * Acute trauma patient with suspected head injury * Time from injury to measurement procedure not longer than 8 hours 15 min * Head CT prescribed by treating physician * Patient is ≥ 18 years of age * Patient is deemed clinically stable

Exclusion criteria

(groups A and B): * Patient has suspected cervical spine fracture, per the Investigator's judgement * Patient has by CT confirmed cervical spine fracture * Patient has confirmed skull fracture with risk for dislocation. * Patient has a shunt or other foreign object implanted intracranially (if known by medical records) * Patient has agraffes or other metal parts, thick bandage (\>1cm), or other foreign materials attached to the head that are deemed to interfere with the diagnostic procedure. * Patient diagnosed with a condition associated with risk of poor protocol compliance * The measurement procedure is deemed to interfere with the standard of care * Other condition or symptoms preventing the patient from entering the trial, per the investigator´s judgment Inclusion Criteria (Group C): * Patient is ≥ 18 years of age * Signed informed consent

Design outcomes

Primary

MeasureTime frameDescription
Ability to detect intracranial hemorrhage3.5 yearsThe ability of the device MD100, with and without brain biomarkers (Aβ40, Aβ42, GFAP, H-FABP, S100B, NF-L, NSE, UCH-L1 and IL-10) to detect traumatic intracranial haemorrhage, as measured by the area under the receiver operating characteristics curve.

Secondary

MeasureTime frameDescription
Estimating anatomic position of intracranial hemorrhage3.5 yearsThe accuracy for estimating the position of intracranial hemorrhage with microwave data.
Estimating volume of intracranial hemorrhage3.5 yearsThe accuracy for estimating the volume of intracranial hemorrhage with microwave data.
Adverse events of microwave scan3.5 yearsAny adverse events occurring within 24 hours of microwave scan

Countries

Sweden

Contacts

Primary ContactTomas J Vedin, MD, PhD
tomas.vedin@med.lu.se+464263131
Backup ContactJacob Lundager Foberg, MD, PhD
jakob.lundager-forberg@med.lu.se+464261000

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 15, 2026